MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeffrey, S. S.
Right arrow Articles by Botstein, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeffrey, S. S.
Right arrow Articles by Botstein, D.
Molecular Interventions 2:101-109 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics

Review

Expression Array Technology in the Diagnosis and Treatment of Breast Cancer

Stefanie S. Jeffrey1, Michael J. Fero2, Anne-Lise Børresen-Dale3 and David Botstein2

1 Departments of Surgery and
2 Genetics Stanford University School of Medicine Stanford CA 94305 and
3 Department of Genetics Norwegian Radium Hospital University of Oslo, Oslo, Norway.

Correspondence: SSJ. E-mail ssj{at}stanford.edu; fax 650-498-6250.


The most common group of cancers among American women involves malignancies of the breast. Breast cancer is a complex disease, involving several different types of tissues and specific cells with various functions, that is categorized into many distinct subtypes. Microarray analysis has recently revealed that different biological subtypes of breast cancer are accompanied by differences in their specific gene expression profile. Because breast tissue (and breast cancer) is heterogeneous, microarray analysis may provide clinicians with a better understanding of how to treat each specific case. Thus, microarray analysis may translate basic research data into more confident diagnoses, specifically designed treatment regimens geared to each patient's needs, and better clinical prognoses.




This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis
Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas
Mol. Cell. Proteomics, April 1, 2005; 4(4): 570 - 581.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.